Lenient versus Strict Rate Control in Patients with Atrial Fibrillation
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation. METHODS: We randomly assigned 614 patients with permanent atrial fibrillation to undergo a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute). The primary outcome was a composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. The duration of follow-up was at least 2 years, with a maximum of 3 years. RESULTS: The estimated cumulative incidence of the primary outcome at 3 years was 12.9% in the lenient-control group and 14.9% in the strict-control group, with an absolute difference with respect to the lenient-control group of -2.0 percentage points (90% confidence interval, -7.6 to 3.5; P<0.001 for the prespecified noninferiority margin). The frequencies of the components of the primary outcome were similar in the two groups. More patients in the lenient-control group met the heart-rate target or targets (304 [97.7%], vs. 203 [67.0%] in the strict-control group; P<0.001) with fewer total visits (75 [median, 0], vs. 684 [median, 2]; P<0.001). The frequencies of symptoms and adverse events were similar in the two groups. CONCLUSIONS: In patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control and is easier to achieve. (ClinicalTrials.gov number, NCT00392613.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was no difference in a composite of clinical events (14.9% in the strict rate control group, 12.9% in the lenient group), 560 NYHA class, or hospitalizations.560, 561”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [560]
Citations
Cites
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
A comparison of rate control and rhythm control in patients with atrial fibrillation
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa021328 · Cited by 4,405
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Self-citationVan Gelder, I. C., Hagens, V. E., Bosker, H. A., Kingma, J. H., Kamp, O., Kingma, T., Said, S. A., Darmanata, J. I., Timmermans, A. J. M., Tijssen, J. G. P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021375 · Cited by 2,359
Self-citationEffect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Hohnloser, S. H., Crijns, H. J. G. M., van Eickels, M., Gaudin, C., Page, R. L., Torp-Pedersen, C., & Connolly, S. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0803778 · Cited by 1,129
Self-citationAtrial Fibrillation and Heart Failure: Treatment Considerations for a Dual Epidemic
Anter, E., Jessup, M., & Callans, D. J. (2009) · Circulation · doi:10.1161/circulationaha.108.821306 · Cited by 678
Lechat, P., Hulot, J.-S., Escolano, S., Mallet, A., Leizorovicz, A., Werhlen-Grandjean, M., Pochmalicki, G., & Dargie, H. (2001) · Circulation · doi:10.1161/01.cir.103.10.1428 · Cited by 525
Nerheim, P., Birger-Botkin, S., Piracha, L., & Olshansky, B. (2004) · Circulation · doi:10.1161/01.cir.0000135472.28234.cc · Cited by 378
Van Gelder, I. C., Crijns, H. J. G. M., Blanksma, P. K., Landsman, M. L. J., Posma, J. L., Van Den Berg, M. P., Meijler, F. L., & Lie, K. I. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90352-d · Cited by 269
Self-citationConnolly, S. J., Crijns, H. J. G. M., Torp-Pedersen, C., van Eickels, M., Gaudin, C., Page, R. L., & Hohnloser, S. H. (2009) · Circulation · doi:10.1161/circulationaha.109.875252 · Cited by 261
Self-citation
Cited by
Items 401–500 of 999
Intravenous Continuous Infusion vs. Oral Immediate-release Diltiazem for Acute Heart Rate Control
Means, K., Gentry, A. E., & Nguyen, T. (2018) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2017.10.33832 · Cited by 11
Acute Management of Atrial Fibrillation
Beck, H., & See, V. Y. (2012) · Cardiology Clinics · doi:10.1016/j.ccl.2012.07.007 · Cited by 11
Medical emergencies: atrial fibrillation and myocardial infarction
Somasundaram, K., & Ball, J. (2012) · Anaesthesia · doi:10.1111/anae.12050 · Cited by 11
“For a review of this topic see [21–23].”
BackgroundChin, A., Badri, M., Ntusi, N., & Okreglicki, A. M. (2012) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2011-019 · Cited by 10
Atrial fibrillation: An anesthesiologist's perspective
Liao, H.-R., Poon, K.-S., & Chen, K. (2013) · Acta anaesthesiologica Taiwanica · doi:10.1016/j.aat.2013.03.010 · Cited by 10
Atrial Fibrillation: Pharmacological Therapy
Patel, C., Salahuddin, M., Jones, A., Patel, A., Yan, G., & Kowey, P. R. (2011) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2011.01.001 · Cited by 12
Current Evidence and Recommendations for Rate Control in Atrial Fibrillation
Maan, A., MANSOUR, M. C., Ruskin, J. N., Heist, E. K., Medicine, A. P. O., & Medicine, A. P. O. (2013) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2013.2.1.30 · Cited by 11
“In the subsequent randomised Rate control Efficacy in Permanent Atrial Fibrillation (RACE II) trial; a lenient rate control strategy (resting heart rate <110 bpm) was demonstrated to be as effective as strict rate control (resting heart rate <80 bpm and heart rate during moderate exercise <110 bpm) for the composite o…”
BackgroundMehra, N. S., Kowlgi, G. N., & Deshmukh, A. J. (2020) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-020-00645-5 · Cited by 10
Bauersachs, J. K., & Veltmann, C. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1733 · Cited by 12
Prevention of cardioembolic stroke in patients with atrial fibrillation
Weber, R., Diener, H., & Weimar, C. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.103 · Cited by 8
Jackman, W. M., Stevenson, W. G., Estes, M., Richard, L., Ezekowitz, M. D., Curtis, A. B., January, C. T., Ellenbogen, K. A., & James, E. A. (2011) · Cited by 9
Packer, M. (2019) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14236 · Cited by 9
Manuel, A. M., Almeida, J. G., Fonseca, P., Monteiro, J. P., Guerreiro, C., Barbosa, A. R., Teixeira, P., Ribeiro, J., Santos, E., Rosas, F., et al. (2021) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.05.016 · Cited by 9
“Clinical trials have demonstrated that in about one quarter of these patients, an adequate rate control strategy cannot be achieved.(4,5) Currently, in patients with supraventricular arrhythmias who are unresponsive or intolerant to pharmacological therapy, rhythm control may be achieved with electrical cardioversion…”
BackgroundKato, N., Kinugawa, K., Imamura, T., Muraoka, H., Maki, H., Toshiro, I., Hatano, M., Yao, A., & Nagai, R. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.03.050 · Cited by 9
Ziegler, P., Koehler, J. L., & Verma, A. (2012) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2012.03349.x · Cited by 9
Ventricular Rate Control of Atrial Fibrillation in Heart Failure
Rienstra, M., & Gelder, I. C. V. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.004 · Cited by 11
Rodriguez, Y., Althouse, A. D., ADELSTEIN, E. C., Jain, S. K., Mendenhall, G. S., Saba, S., Shalaby, A. A., Voigt, A., & Wang, N. C. (2016) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12981 · Cited by 9
Albakri, A. (2018) · Integrative Molecular Medicine · doi:10.15761/imm.1000324 · Cited by 9
Han, Q., Zhang, C., You, S., Zheng, D., Zhong, C., Dong, H., Wang, X., Pei, S., Cao, Y., & Liu, C. (2020) · Circulation Journal · doi:10.1253/circj.cj-19-0946 · Cited by 11
Atrial fibrillation ablation in heart failure: What do we know? What can we do?
Chiocchini, A., Terricabras, M., & Verma, A. (2020) · EP Europace · doi:10.1093/europace/euaa217 · Cited by 9
Atrial Fibrillation in Heart Failure
Havmöller, R., & Chugh, S. S. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0108-6 · Cited by 10
Prognostic Value of Cardiopulmonary Exercise Testing in Cardiac Patients With Atrial Fibrillation
Tsuneoka, H., Koike, A., Nagayama, O., Sakurada, K., Kato, J., Sato, A., Yamashita, T., & Aonuma, K. (2012) · International Heart Journal · doi:10.1536/ihj.53.102 · Cited by 9
Campanini, M., Frediani, R., Artom, A., Pinna, G., Valerio, A., Regina, M. L., Marengo, S., Pinto, G. L., Signore, E. D., Bonizzoni, E., et al. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328348e5ce · Cited by 9
Catheter ablation for atrial fibrillation in the elderly
Haegeli, L., Wölber, T., & Duru, F. (2013) · Clinical Practice · doi:10.2217/cpr.13.23 · Cited by 9
Atrial Fibrillation: Antiarrhythmic Therapy
Psotka, M. A., & Lee, B. K. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.07.004 · Cited by 9
“The rate control efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control II (RACE II) randomized, open-label trial compared maintenance of a target resting HR lower than 80 BPM in the strict group vs lower than 110 BPM in the lenient group in 614 patients with permanent AF.(3…”
MethodEPIDEMIOLOGY AND MANAGEMENT OF HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION
Osmolovskaya, Y. F., Романова, Н. В., Жиров, И. В., & Tereschenko, S. N. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-10-93-97 · Cited by 10
Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017
Kanagaratnam, L. B., Kowey, P. R., & Whalley, D. W. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.05.134 · Cited by 10
Wong, B. M., Green, M. S., & Stiell, I. G. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.08.040 · Cited by 9
Atrial fibrillation and arterial hypertension
Баранова, Е. И. (2011) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2011--4- · Cited by 14
Rate versus rhythm control in atrial fibrillation.
Frankel, G., Kamrul, R., Kosar, L., & Jensen, B. (2013) · Europe PMC (PubMed Central) · Cited by 15
Calidad de vida en pacientes con fibrilación auricular
Camm, A. J. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70263-3 · Cited by 9
Review: Sex-related differences in the treatment of cardiac arrhythmia
Haum, M., Kellnar, A., Thienel, M., & Lackermair, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108388 · Cited by 9
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Lalani, G., Trikha, R., Krummen, D. E., & Narayan, S. M. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0478 · Cited by 11
Lacoste, J. L., Szymanski, T. W., Avalon, J. C., Kabulski, G. M., Kohli, U., Marrouche, N. F., Singla, A., Balla, S., & Jahangir, A. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00529-6 · Cited by 12
“Patients enrolled in the trial had a mean age of 68 years, were 66% male, and had a mean duration of AF of 18 months [26].”
BackgroundKommentar zu den Leitlinien der ESC zum Vorhofflimmern
Kirchhof, P. F., Goette, A., Gulba, D. C., Hindricks, G., & Hohnloser, S. H. (2012) · Der Kardiologe · doi:10.1007/s12181-011-0395-2 · Cited by 18
Exercise Heart Rate Acceleration Patterns during Atrial Fibrillation and Sinus Rhythm
Buber, J., Glikson, M., Eldar, M., & Luria, D. M. (2011) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2011.00463.x · Cited by 8
Advances in treatment and management
Connolly, S. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.206 · Cited by 8
“The Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control (RACE)-II tria”
MethodAtrial fibrillation and heart failure: a bad combination
Leong‐Sit, P., & TANG, A. S. L. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000144 · Cited by 9
“not confer a significant advantage versus lenient rate control [26].”
Naegele, M., Flammer, A. J., Enseleit, F., & Ruschitzka, F. T. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14295 · Cited by 9
Cumyn, A., Sauvé, N., & Rey, É. (2017) · Obstetric Medicine · doi:10.1177/1753495x16685684 · Cited by 8
She, F., Ma, Y., Li, Y., Li, L., Xu, W., Wang, H., & Cui, M. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-01293-3 · Cited by 7
Current pharmacotherapeutic strategies for cardiac arrhythmias in heart failure
Correa, A. A., Rochlani, Y. M., & Aronow, W. S. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1703950 · Cited by 8
“patients with permanent AF to either a lenient strategy (target heart rate <110 bpm) or a strict strategy (target heart rate at rest <80 bpm and <110 bpm with moderate exercise) [54].”
BackgroundZaman, N., Naccarelli, G. V., & Foy, A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420987451 · Cited by 10
“Studies performed after the AFFIRM trial such as RACE II indicated similar outcomes in patients with strict (less than 80) and lenient (less than 110) heart rate control with increasing morbidity and mortality toward the strict rate control group.(32) Perhaps, a mortality and hospitalization benefit would be observed…”
MethodElshazly, M. B., Wilkoff, B. L., Tarakji, K. G., Wu, Y., Donnellan, E., Khalil, C. A., Asaad, N., Jaber, W. A., Wazni, O. M., & Cho, L. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007451 · Cited by 8
Oka, S., Kai, T., Hoshino, K., Watanabe, K., Nakamura, J., Abe, M., & Watanabe, A. (2021) · International Heart Journal · doi:10.1536/ihj.20-266 · Cited by 8
Li, C., Wang, H., Li, M., Qiu, X., Wang, Q., Sun, J., Yang, M., Feng, X., Meng, S., Zhang, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.821960 · Cited by 10
“We compared AF patients with different control levels of ventricular rate (resting ventricular rate under 80 bpm or between 80 and 110 bpm) about various MI ECG events, and there was no statistically significant difference, which is consistent with findings from previous research that lenient rate control was non-infe…”
ResultTélésurveillance de la fibrillation auriculaire : étude de faisabilité et résultats sur 200 patients
Dary, P. (2013) · European Research in Telemedicine / La Recherche Européenne en Télémédecine · doi:10.1016/j.eurtel.2013.10.005 · Cited by 8
Schryver, N. D., Scavée, C., Marchandise, S., Pasquet, A., de Meester, C., & de Waroux, J. L. P. (2014) · EP Europace · doi:10.1093/europace/euu033 · Cited by 9
Management of atrial fibrillation and concomitant coronary artery disease
Martin, R. I. R., & Bates, M. G. D. (2017) · Continuing Cardiology Education · doi:10.1002/cce2.55 · Cited by 10
“Where symptoms or tachycardia-induced myopathy are present despite lenient rate control, a lower target resting rate of <80 bpm should be maintained [32].”
BackgroundAtrial arrhythmias after pulmonary thromboendarterectomy
Farasat, S., Papamatheakis, D. G., Poch, D. S., Higgins, J. R., Pretorius, V. G., Madani, M. M., Auger, W. R., Kerr, K. M., & Fernandes, T. M. (2019) · Journal of Cardiac Surgery · doi:10.1111/jocs.14028 · Cited by 8
Medical, interventional, and surgical treatment strategies for atrial fibrillation
Willems, S., Gunawardene, M., Eickholt, C., Hartmann, J., Schmoeckel, M., & Schäffer, B. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0002 · Cited by 12
Cihak, R. J., Heinc, P., Haman, L., Fiala, M., Neužil, P., & Toman, O. (2011) · Cor et Vasa · doi:10.33678/cor.2011.193 · Cited by 9
Supraventricular and Ventricular Arrhythmias
Goel, R., Srivathsan, K. S., & Mookadam, M. (2013) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.002 · Cited by 10
Lian, C., Zhang, X., Li, J., Li, J., Shi, S., Wang, L., Guo, Z., Liu, N., Wang, H., Shuai, S. H. I., et al. (2025) · International Dental Journal · doi:10.1016/j.identj.2024.12.029 · Cited by 8
Sp, G., Панченко, Е. П., Mironov, N. Y., Михайловна, Б. М., Gagloeva, D. A., Elfimova, E. M., Станиславовна, К. Е., Laiovich, L. I., Litvin, A. Y., Maykov, E. B., et al. (2025) · Eurasian heart journal · doi:10.38109/2225-1685-2025-3-6-77 · Cited by 9
The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy
Cohen, M. C., & Boiangiu, C. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0086-1 · Cited by 7
Atrial Fibrillation in the Aging Heart: Pharmacological Therapy and Catheter Ablation in the Elderly
Haegeli, L. M., & Duru, F. (2011) · Future Cardiology · doi:10.2217/fca.11.22 · Cited by 6
Antiarrhythmic Treatment in Heart Failure
Könemann, H., Güler-Eren, S., Ellermann, C., Frommeyer, G., & Eckardt, L. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-023-00642-w · Cited by 10
“A lenient rate control (target resting heart rate 110 bpm) is considered to be an acceptable approach, as data from the RACE II trial and a pooled analysis of the historic RACE and AFFIRM trials failed to show differences in outcome comparing lenient and strict rate control strategies [24, 25].”
MethodLuo, X., Xiong, Q., Xu, J., Hong, K., Peng, Q., Li, J., Cheng, X., Lip, G. Y. H., & Su, H. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.04.048 · Cited by 7
2014 Indonesian Heart Association Guidelines of Management of Atrial Fibrillation
Yuniadi, Y., Hanafy, D. A., Rahardjo, S. B., Tondas, A. E., Maharani, E., Hermanto, D. Y., & Munawar, M. (2015) · Indonesian Journal of Cardiology · doi:10.30701/ijc.v35i2.398 · Cited by 11
Atrioventricular junctional ablation: The good, the bad, the better
Scherlag, B. J., Elkholey, K., Stavrakis, S., Jackman, W. M., & Po, S. S. (2020) · Heart Rhythm O2 · doi:10.1016/j.hroo.2020.06.003 · Cited by 7
“Moreover, clinical trials showed that strict rate control cannot be achieved in at least one-quarter of patients.(2,8) Therefore, in specific conditions, AVJA with permanent pacemaker (PPM) implantation represents a particularly useful therapeutic intervention and last resort in rate control.”
BackgroundFeinberg, J. B., Olsen, M. H., Brandes, A., Raymond, L., Nielsen, W. B., Nielsen, E. E., Steensgaard-Hansen, F., Dixen, U., Pedersen, O. D., Gang, U. J. O., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044744 · Cited by 7
Koniari, I. C., Artopoulou, E., Velissaris, D., Kounis, N. G., & Tsigkas, G. (2021) · PubMed Central · doi:10.11909/j.issn.1671-5411.2021.05.003 · Cited by 17
“The optimal ventricular rate during exercise is not clarified, but may be < 110 beats/min during light exercise.([185]) Beta-blockers, digoxin and their combination may be useful in the control of the ventricular rate.”
BackgroundHanon, O., Assayag, P., Belmin, J., Collet, J., Émeriau, J. P., Fauchier, L., Forette, F., Friocourt, P., Gentric, A., Leclercq, C., et al. (2013) · Gériatrie et Psychologie Neuropsychiatrie du Viellissement · Cited by 7
Hirano, K., Yamashita, T., Suzuki, S. S., Hayama, E., Matsuoka, J., Otsuka, T., Sagara, K., Fu, L.-T., Sawada, H., Aizawa, T., et al. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.02.002 · Cited by 7
Pharmacotherapeutic decision-making for patients with atrial fibrillation
Kalus, J. S. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100149 · Cited by 7
Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Weijs, B., Schotten, U., & Crijns, H. J. G. M. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140825150057 · Cited by 9
“rhythm control trials have shown that a rate control approach is not inferior for prevention of morbidity and mortality in AF patients, there is no evidence that the arrhythmia itself deteriorates outcome in AF patients [52, 53, 213-216].”
BackgroundSelf-citationGood, E. D., & Rogers, F. J. (2012) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2012.112.6.334 · Cited by 8
Association of atrial fibrillation risk alleles and response to acute rate control therapy
Barrett, T. W., Self, W. H., Darbar, D., Jenkins, C. A., Wasserman, B. S., Kassim, N. A., Casner, M., & Shoemaker, M. B. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.01.034 · Cited by 7
“A ventricular rate b110 bpm to define rate control was chosen based on data suggesting that this target goal is noninferior to strict rate control in the outpatient setting [19].”
MethodChinushi, M., & Iijima, K. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0080 · Cited by 7
Cardiac Arrhythmias with Supraventricular Origin
ZIMETBAUM, P. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00064-6 · Cited by 10
Arrhythmia-Induced Cardiomyopathy: Prevalent, Under-recognized, Reversible
Dhawan, R., & Gopinathannair, R. (2017) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1776 · Cited by 7
DeMeester, S., Hess, R. A., Hubbard, B. L., LeClerc, K., Ferraro, J., & Albright, J. J. (2018) · Academic Emergency Medicine · doi:10.1111/acem.13383 · Cited by 7
Dalgaard, F., Ruwald, M. H., Lindhardt, T. B., Gislason, G., Torp-Pedersen, C. T., & Pallisgaard, J. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195175 · Cited by 8
A Clinical Perspective on Atrial Fibrillation
Platonov, P. G., & Corino, V. (2018) · Series in bioengineering · doi:10.1007/978-3-319-68515-1_1 · Cited by 13
Zimmerman, D. E., Jachim, L., Iaria, A., Brun, C., & Covvey, J. R. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12731 · Cited by 7
Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation
Ahn, M., Yoo, B., Son, J., Yu, M. H., Kang, D. R., Lee, H., Jeon, E., Kim, J., Chae, S. C., Baek, S. H., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e278 · Cited by 9
Atrial fibrillation and flutter – the state of the art. Part 2
Janion−Sadowska, A., Turek, Ł., Dudek, A., Andrychowski, J., & Sadowski, M. (2021) · Medical Studies · doi:10.5114/ms.2021.109530 · Cited by 9
Wan, H., Yang, Y., Zhu, J., Shao, X., Wang, J., Huang, B., & Zhang, H. (2015) · Medicine · doi:10.1097/md.0000000000000920 · Cited by 8
“The relationship between ventricular heart rate and mortality among the patients with permAF in the present study was inconsistent with that noted in previous studies.(3,13,14) Analysis of the pooled data from both the Rate Control Efficacy in Permanent Atrial Fibrillation (RACE) (28% with CADs) and Atrial Fibrillatio…”
ResultRate Control in Atrial Fibrillation: Many Questions Still Unanswered
Gelder, I. C. V., Hobbelt, A. H., Mulder, B. A., & Rienstra, M. (2015) · Circulation · doi:10.1161/circulationaha.115.018952 · Cited by 7
“An early report on predictors for mortality in the AFFIRM trial reported that digoxin was independently associated with increased mortality in at CENTRAL MICHIGAN UNIV LIBR on September 18, 2015http://circ.ahajournals.org/Downloaded from 6 patients with AF.16 More recently two additional post-hoc analyses of AFFIRM on…”
InfluentialGunawardhana, M., Kulathilaka, A., & Zhao, J. (2025) · Discover Artificial Intelligence · doi:10.1007/s44163-025-00324-7 · Cited by 10
“Some studies [88] suggest that lenient rate control is as effective as strict rate control while being easier to achieve in patients with permanent atrial fibrillation.”
Baumgartner, T., Kaelin-Friedrich, M., Makowski, K., Noti, F., Schaer, B. A., Haeberlin, A., Badertscher, P., Kozhuharov, N., Baldinger, S. H., Seiler, J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164927 · Cited by 6
“Despite significant advantages in catheter ablation [2], rhythm control by means of catheter ablation and/or medication is not attainable in a substantial proportion of patients with atrial fibrillation, in particular in patients with persistent, long standing and permanent atrial fibrillation [3,4].”
BackgroundErmert, L., Kreimer, F., Quast, D. R., Pflaumbaum, A., Mügge, A., & Gotzmann, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.940060 · Cited by 6
Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation
Chinese Society of Cardiology, C. M. A., & Heart Rhythm Committee of Chinese Society of Biomedical Engineering (2024) · Cardiology Discovery · doi:10.1097/cd9.0000000000000123 · Cited by 9
Atrial Fibrillation in Heart Failure in the Older Population
Heck, P. M., Lee, J., & Kistler, P. M. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.007 · Cited by 8
“Previously, guidelines have advocated the use of “strict” rate control(10) with resting heart rate less than 80 beats per minute, but recent evidence suggests that a more lenient target of less than 110 beats per minute could be adopted.(11) The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)…”
BackgroundCurrent management of atrial fibrillation
Samardhi, H., Santos, M. J., Denman, R. A., Walters, D., & Bett, N. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.058 · Cited by 6
Gu, Y., Feng, L., Xu, Y., & Zhao, Y. (2014) · Journal of International Medical Research · doi:10.1177/0300060514543034 · Cited by 7
Atrial Fibrillation in Patients with Heart Failure: Current State and Future Directions
Mene-Afejuku, T. O., Lopez, P. D., Akinlonu, A. A., Dumancas, C. Y., Visco, F., Mushiyev, S., & Pekler, G. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0276-1 · Cited by 6
BET 1: Lenient or strict rate control for atrial fibrillation
Stratton, T., & Nasser, L. (2018) · Emergency Medicine Journal · doi:10.1136/emermed-2018-208261.1 · Cited by 6
Gillmann, H.-J., Busche, P., Leffler, A., & Stueber, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-06639-0 · Cited by 6
Yu, L., Jiang, R., Sun, Y., Ye, Y., Zhang, P., Liu, Q., Sheng, X., Zhang, Z., Chen, S., Fu, G., et al. (2022) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14507 · Cited by 6
Rate Versus Rhythm Control for Atrial Fibrillation
Shin, E. D., Tran, H., Ramalingam, N. D., Liu, T., & Fan, E. (2023) · The Permanente Journal · doi:10.7812/tpp/23.151 · Cited by 6
‘Inappropriate’ Sinus Tachycardia: Does the 100 Beats Per Min cut-off matter?
Hottigoudar, R. U., & Gopinathannair, R. (2013) · Future Cardiology · doi:10.2217/fca.13.5 · Cited by 6
Atrial Fibrillation in Dialysis Patients: Time to Abandon Warfarin?
Brancaccio, D., Neri, L., Bellocchio, F., Barbieri, C., Amato, C., Mari, F., Canaud, B., & Stuard, S. (2016) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000487 · Cited by 6
Salem, J., Dureau, P., Funck‐Brentano, C., Hulot, J., El-Aissaoui, M., Aïssaoui, N., Urien, S., & Faisy, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.06.004 · Cited by 6
Contemporary Yield of 24-hour Holter Monitoring: Role of Inter-Atrial Block Recognition
Bazán, V., Cediel, G., Cinta, L., Sarrias, A., Isabel, R., Sònia, I., Francisco, E. A., Moré, S. V., Bisbal, F., Villuendas, R., et al. (2019) · Journal of Atrial Fibrillation · doi:10.4022/jafib.2225 · Cited by 9
Arrhythmia-Induced Cardiomyopathies
Dhawan, R., & Gopinathannair, R. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-41967-7_24 · Cited by 6
Crijns, H. J. G. M., & Gelder, I. C. V. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01476-0 · Cited by 6
Self-citationHämmerle, P., Eick, C., Poli, S., Blum, S., Schlageter, V., Bauer, A., Rizas, K. D., Eken, C., Coslovsky, M., Aeschbacher, S., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.684461 · Cited by 6
Metadata
- Authors
- Van Gelder, I. C., Groenveld, H. F., Crijns, H. J. G. M., Tuininga, Y. S., Tijssen, J. G. P., Alings, A. M., Hillege, H. L., Bergsma-Kadijk, J. A., Cornel, J. H., Kamp, O., Tukkie, R., Bosker, H. A., Van Veldhuisen, D. J., & Van den Berg, M. P.
- Affiliations
- University Medical Center Groningen (NL)
- Maastricht University Medical Centre (NL)
- Deventer Ziekenhuis (NL)
- Amsterdam UMC Location University of Amsterdam (NL)
- Medisch Centrum Alkmaar (NL)
- Rijnstate Hospital (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-04-15
- Volume
- 362
- Issue
- 15
- Pages
- 1363-1373
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102129403
- Cited by
- 1,033
- References
- 19
- Citations by year
- 2026: 36 · 2025: 55 · 2024: 59 · 2023: 61 · 2022: 56 · 2021: 63 · 2020: 44 · 2019: 50 · 2018: 45 · 2017: 62 · 2016: 56 · 2015: 51 · 2014: 81 · 2013: 94 · 2012: 83
- FWCI
- 68.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Keywords
- atrial fibrillation, rate control, resting heart rate, non-inferiority, cardiovascular morbidity and mortality, heart failure hospitalization, stroke, hemorrhage, arrhythmic events, anticoagulation
- MeSH terms
- Adrenergic beta-Antagonists, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Calcium Channel Blockers, Female, Follow-Up Studies, Heart Rate, Humans, Male, Middle Aged, Confidence Intervals, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.